Stockscreener 앱 받기
316.67
1.93%
6.00
시간 외 거래:
316.67
전일 마감가:
$310.67
열려 있는:
$313.46
하루 거래량:
1.37M
Relative Volume:
1.63
시가총액:
$18.21B
수익:
$1.98B
순이익/손실:
$420.90M
주가수익비율:
54.22
EPS:
5.84
순현금흐름:
$218.20M
1주 성능:
+22.37%
1개월 성능:
+24.68%
6개월 성능:
+15.11%
1년 성능:
+90.88%
1일 변동 폭
$305.95
$318.86
1주일 범위
$256.00
$318.86
52주 변동 폭
$160.19
$318.86
인슐렛 코퍼레이션 Stock (PODD) Company Profile
명칭
Insulet Corporation
전화
978-600-7000
주소
100 NAGOG PARK, ACTON, MA
PODD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
316.67 | 18.21B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
131.99 | 230.70B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.87 | 154.22B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
388.08 | 145.74B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.81 | 107.03B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.80 | 44.06B | 5.54B | 4.18B | 623.10M | 7.00 |
인슐렛 코퍼레이션 Stock (PODD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-07 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-08-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-04 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-07-28 | 개시 | Wells Fargo | Overweight |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 개시 | BofA/Merrill | Neutral |
| 2020-03-31 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-10 | 개시 | CFRA | Sell |
| 2019-10-23 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-10-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-10-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-06-10 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-04-20 | 개시 | Berenberg | Buy |
| 2018-02-22 | 재확인 | Barclays | Overweight |
| 2018-01-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 개시 | Barclays | Overweight |
모두보기
인슐렛 코퍼레이션 주식(PODD)의 최신 뉴스
Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised - Nasdaq
Analysts Turn Bullish on Insulet Stock (PODD) after Strong Q1 Earnings - MSN
Insulet raises 2025 revenue guidance to 19%-22% growth amid strong Omnipod adoption - MSN
Insulet (PODD) Sees 20.85% Weekly Surge - GuruFocus
S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points - MSN
Insulet Corporation (NASDAQ:PODD) Q1 2025 Earnings Call Transcript - Insider Monkey
Insulet (PODD) Sees Price Target Boost Amid Strong Sales Performance | PODD Stock News - GuruFocus
BTIG raises Insulet stock price target to $330, maintains Buy rating - Investing.com Nigeria
Insulet’s Earnings Call Reveals Strong Growth and Expansion - TipRanks
Insulet (PODD) Price Target Raised by Oppenheimer Analyst | PODD Stock News - GuruFocus
Piper Sandler maintains Overweight rating on Insulet stock By Investing.com - Investing.com Canada
Insulet Seeks $30M In Atty Fees, Costs After Trade Secret Win - Law360
U.S. Indexes Ended Friday Mixed As Insulet Led, Affirm Holdings Lagged - Barron's
New Insulet CEO Ashley McEvoy sets priorities - MedTech Dive
Sector Update: Health Care - marketscreener.com
Canaccord raises Insulet stock target to $331, maintains buy rating - Investing.com
Piper Sandler maintains Overweight rating on Insulet stock - Investing.com
Why Insulet (PODD) Stock Is Trading Up Today - Yahoo Finance
Insulet Stock Soars to Lead S&P 500 Gainers Friday - Investopedia
Tesla, Insulet Surge Among Market Cap Stock Movers on Friday By Investing.com - Investing.com Nigeria
Insulet Q1 beat, Sweetgreen sinks on outlook, Wolfspeed drops - Yahoo Finance
Tesla, Insulet Surge Among Market Cap Stock Movers on Friday - Investing.com Australia
Insulet (NasdaqGS:PODD) Announces $125M Buyback, Raises Revenue Guidance For 2025 - Yahoo Finance
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More - Investopedia
Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad - Benzinga
Trade Desk, Insulet Surge in Friday’s Market Cap Stock Movers By Investing.com - Investing.com Nigeria
Trade Desk, Insulet Surge in Friday’s Market Cap Stock Movers - Investing.com Australia
Insulet Stock Is the Top S&P 500 Performer Today. Here’s Why. - MSN
Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On FridayDefinitive Healthcare (NASDAQ:DH), AvePoint (NASDAQ:AVPT) - Benzinga
Piper Sandler on Insulet Corporation (PODD): 'Strong Update Across the Board' - StreetInsider
Canaccord raises Insulet stock target to $331, maintains buy rating By Investing.com - Investing.com India
BTIG Boosts Price Target for Insulet (PODD) After Strong Q1 Results | PODD Stock News - GuruFocus
Baird Adjusts Price Target on Insulet to $350 From $325, Maintains Outperform Rating - marketscreener.com
Insulet Corporation Exceeds Q1 CY2025 Revenue ExpectationsNews and Statistics - IndexBox
Insulet Corporation (PODD) PT Raised to $331 at Canaccord Genuity - StreetInsider
Insulet Corporation (PODD) PT Raised to $330 at BTIG - StreetInsider
Earnings call transcript: Insulet beats Q1 2025 forecasts, stock surges By Investing.com - Investing.com Nigeria
Insulet Corp (PODD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion By GuruFocus - Investing.com Canada
Insulet Corp (PODD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - GuruFocus
Insulet Corporation Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Insulet beats Q1 2025 forecasts, stock surges - Investing.com Australia
Insulet requests $30 million in attorneys fees after EOFlow trade secret injunction - MLex
Insulet’s (NASDAQ:PODD) Q1: Strong Sales, Stock Soars - Yahoo Finance
Insulet: Q1 Earnings Snapshot - MySA
Insulet's Strong Profit And Innovation Propel Shares Higher - Finimize
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Insulet Q4 2024 slides: revenue tops $2.1B, margins expand as Type 2 diabetes push begins - Investing.com
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Insulet Corp (PODD) Q1 2025 Earnings: Revenue Surges to $569M, Beating Estimates, EPS Falls Short at $0.50 - GuruFocus
Insulet Jumps After Beating Quarterly Forecasts, Raising 2025 Expectations - MSN
Insulet earnings beat by $0.23, revenue topped estimates By Investing.com - Investing.com South Africa
인슐렛 코퍼레이션 (PODD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.95%
자본화:
|
볼륨(24시간):